Cargando…

Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients

BACKGROUND: Hepatocellular carcinoma (HCC) is a major health problem and a primary cause of cancer‐related death worldwide. Although great advances have achieved recently by large‐scale high‐throughput analysis, the precise molecular mechanism underlying HCC progression remains to be clearly elucida...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhong‐Guo, Chen, Jin‐Bin, Zhang, Rong‐Xin, Ye, Ling, Wang, Jun‐Cheng, Pan, Yang‐Xun, Wang, Xiao‐Hui, Li, Wen‐Xuan, Zhang, Yao‐Jun, Xu, Li, Chen, Min‐Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427307/
https://www.ncbi.nlm.nih.gov/pubmed/32609436
http://dx.doi.org/10.1002/cac2.12069
_version_ 1783570853053595648
author Zhou, Zhong‐Guo
Chen, Jin‐Bin
Zhang, Rong‐Xin
Ye, Ling
Wang, Jun‐Cheng
Pan, Yang‐Xun
Wang, Xiao‐Hui
Li, Wen‐Xuan
Zhang, Yao‐Jun
Xu, Li
Chen, Min‐Shan
author_facet Zhou, Zhong‐Guo
Chen, Jin‐Bin
Zhang, Rong‐Xin
Ye, Ling
Wang, Jun‐Cheng
Pan, Yang‐Xun
Wang, Xiao‐Hui
Li, Wen‐Xuan
Zhang, Yao‐Jun
Xu, Li
Chen, Min‐Shan
author_sort Zhou, Zhong‐Guo
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) is a major health problem and a primary cause of cancer‐related death worldwide. Although great advances have achieved recently by large‐scale high‐throughput analysis, the precise molecular mechanism underlying HCC progression remains to be clearly elucidated. We investigated the relationship between Tescalcin (TESC), a candidate oncogene, and clinicopathological features of HCC patients and explored the role of TECS in HCC development. METHODS: To identify new genes involved in HCC development, we analyzed The Cancer Genome Atlas liver cancer database, and TESC was selected for further investigation. HCC tissue microarray analysis for TESC and its association with clinicopathological features were performed to investigate its clinical significance. TESC was knocked down by using short‐hairpin RNAs. Cell proliferation was analyzed by WST‐1 assay and cell counting. Cell apoptosis was tested by fluorescence‐activated cell sorting. A subcutaneous xenograft tumor model in nude mice was established to determine the in vivo function of TESC. Affymetrix microarray was used to identify its molecular mechanism. RESULTS: TESC was significantly increased in HCC tissues compared with the adjacent normal liver tissues. High expression of TESC was detected in 61 of 172 HCC patients by tissue microarray. Large tumor (> 5 cm) and elevated total bilirubin were associated with high TESC expression (both P < 0.050). In multivariate analysis, TESC was identified as an independent prognostic factor for short overall survival of HCC patients. TESC knockdown impaired HCC cell growth in vitro and in vivo. TESC knockdown significantly increased cell apoptosis in HCC cell lines. Furthermore, Affymetrix microarray analysis revealed that TESC knockdown inhibited tumor proliferation‐related pathways while activated cell death‐related pathways. CONCLUSION: TESC was identified as an independent prognostic factor for short overall survival of HCC patients, and was critical for HCC cell proliferation and survival.
format Online
Article
Text
id pubmed-7427307
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74273072020-08-16 Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients Zhou, Zhong‐Guo Chen, Jin‐Bin Zhang, Rong‐Xin Ye, Ling Wang, Jun‐Cheng Pan, Yang‐Xun Wang, Xiao‐Hui Li, Wen‐Xuan Zhang, Yao‐Jun Xu, Li Chen, Min‐Shan Cancer Commun (Lond) Original Articles BACKGROUND: Hepatocellular carcinoma (HCC) is a major health problem and a primary cause of cancer‐related death worldwide. Although great advances have achieved recently by large‐scale high‐throughput analysis, the precise molecular mechanism underlying HCC progression remains to be clearly elucidated. We investigated the relationship between Tescalcin (TESC), a candidate oncogene, and clinicopathological features of HCC patients and explored the role of TECS in HCC development. METHODS: To identify new genes involved in HCC development, we analyzed The Cancer Genome Atlas liver cancer database, and TESC was selected for further investigation. HCC tissue microarray analysis for TESC and its association with clinicopathological features were performed to investigate its clinical significance. TESC was knocked down by using short‐hairpin RNAs. Cell proliferation was analyzed by WST‐1 assay and cell counting. Cell apoptosis was tested by fluorescence‐activated cell sorting. A subcutaneous xenograft tumor model in nude mice was established to determine the in vivo function of TESC. Affymetrix microarray was used to identify its molecular mechanism. RESULTS: TESC was significantly increased in HCC tissues compared with the adjacent normal liver tissues. High expression of TESC was detected in 61 of 172 HCC patients by tissue microarray. Large tumor (> 5 cm) and elevated total bilirubin were associated with high TESC expression (both P < 0.050). In multivariate analysis, TESC was identified as an independent prognostic factor for short overall survival of HCC patients. TESC knockdown impaired HCC cell growth in vitro and in vivo. TESC knockdown significantly increased cell apoptosis in HCC cell lines. Furthermore, Affymetrix microarray analysis revealed that TESC knockdown inhibited tumor proliferation‐related pathways while activated cell death‐related pathways. CONCLUSION: TESC was identified as an independent prognostic factor for short overall survival of HCC patients, and was critical for HCC cell proliferation and survival. John Wiley and Sons Inc. 2020-07-01 /pmc/articles/PMC7427307/ /pubmed/32609436 http://dx.doi.org/10.1002/cac2.12069 Text en © 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zhou, Zhong‐Guo
Chen, Jin‐Bin
Zhang, Rong‐Xin
Ye, Ling
Wang, Jun‐Cheng
Pan, Yang‐Xun
Wang, Xiao‐Hui
Li, Wen‐Xuan
Zhang, Yao‐Jun
Xu, Li
Chen, Min‐Shan
Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
title Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
title_full Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
title_fullStr Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
title_full_unstemmed Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
title_short Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
title_sort tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427307/
https://www.ncbi.nlm.nih.gov/pubmed/32609436
http://dx.doi.org/10.1002/cac2.12069
work_keys_str_mv AT zhouzhongguo tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT chenjinbin tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT zhangrongxin tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT yeling tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT wangjuncheng tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT panyangxun tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT wangxiaohui tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT liwenxuan tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT zhangyaojun tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT xuli tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients
AT chenminshan tescalcinisanunfavorableprognosisfactorthatregulatscellproliferationandsurvivalinhepatocellularcarcinomapatients